Physician profile
Diane M Horowitz
NPI 1275774101
$18,043.23
in general payments reported to CMS, 2019-2025
13 companies · $6,710 in 2025
The $6,710 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.56 · 2023: $7,555 · 2024: $3,731 · 2025: $6,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,044 · Consulting Fee: $3,379 · Honoraria: $2,680 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,160 · Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,043.73 |
| Consulting Fee | $3,379.08 |
| Honoraria | $2,680.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,159.78 |
| Food and Beverage | $1,732.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,208.08 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $4,391.04 | 2023-2025 | Tremfya |
| Pfizer INC. | $4,381.18 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $995.31 | 2023 | |
| Abbvie INC. | $525.00 | 2025 | |
| Genentech, INC. | $457.73 | 2025 | |
| Merck Sharp & Dohme LLC | $47.56 | 2019 | |
| Kerecis Limited | $22.41 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.92 | 2025 | Cabtreo |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.